Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study.

Content Provider	Europe PMC
Author	Hur, Joon Young Yoon, Sang Eun Kim, Seok Jin Kim, Won Seog
Copyright Year	2020
Abstract	Background Immune checkpoint inhibitors have demonstrated efficacy in the treatment of classical Hodgkin’s lymphoma (cHL). We analyzed the efficacy and safety of pembrolizumab or nivolumab in patients with pretreated cHL. Methods Clinical data from the cancer chemotherapy registry of Samsung Medical Center were retrospectively analyzed to study patients with cHL treated with pembrolizumab or nivolumab between Oct 2015 and Dec 2018. Results Of the 20 patients, seven (35%) were enrolled in the study after a relapse following autologous hematopoietic stem cell transplantation (ASCT) and 12 (60%) after a relapse following receipt of brentuximab vedotin (BV). Sixteen (80%) patients received pembrolizumab, and four (20%) patients received nivolumab. The complete remission rate was 45% (9/20), and 30% (6/20) of patients achieved partial remission, for an overall response rate (RR) of 75% [15/20; 95% confidence interval (CI), 34.7‒93.3]. With a median follow-up duration of 14 months, the median PFS was 18 months (95% CI, 2.4‒33.5 mo), and the median OS was 36 months [95% CI, 36-not applicable (NA) mo]. Pembrolizumab and nivolumab were generally well tolerated. Conclusion In this study, pembrolizumab and nivolumab both demonstrated clinical efficacy and tolerability in patients with cHL who failed previous chemotherapy or ASCT.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7343550&blobtype=pdf
ISSN	2287979X
Volume Number	55
DOI	10.5045/br.2020.2020014
PubMed Central reference number	PMC7343550
Issue Number	2
PubMed reference number	32595170
Journal	Blood research [Blood Res]
e-ISSN	22880011
Language	English
Publisher	Korean Society of Hematology
Publisher Date	2020-06-01
Access Restriction	Open
Rights License	This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2020 Korean Society of Hematology
Subject Keyword	Pembrolizumab Nivolumab Hodgkin’s lymphoma
Content Type	Text
Resource Type	Article
Subject	Hematology